Neuroendocrine tumor liver metastases: Use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response

Radiology

Volumn 263, Issue 1, 2012, Pages 139-148

  Miyazaki, Keiko ^a   Orton, Matthew R ^a   Davidson, Robert L ^a   D'Arcy, James A ^a   Lewington, Valerie ^b   Koh, Tong San ^c   Thng, Choon Hua ^d   Leach, Martin O ^a   Collins, David J ^a   Koh, Dow Mu ^e  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM DOTATOC Y 90; (DOTA(0) PHE(1) TYR(3))OCTREOTIDE; (DOTA(0)-PHE(1)-TYR(3))OCTREOTIDE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GADOLINIUM PENTETATE;

ADULT; AGED; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG DISTRIBUTION; DYNAMIC CONTRAST ENHANCED NUCLEAR MAGNETIC RESONANCE IMAGING; FEASIBILITY STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; LIVER METASTASIS; MALE; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; TREATMENT RESPONSE; TUMOR ATRIAL FLOW FRACTION; TUMOR DISTRIBUTION VOLUME; TUMOR PORTAL VENOUS BLOOD FLOW; VOXEL BASED MORPHOMETRY; WHOLE LIVER DISTRIBUTION VOLUME; COMPUTER ASSISTED DIAGNOSIS; DISCRIMINANT ANALYSIS; LIVER TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AREA UNDER CURVE; CONTRAST MEDIA; DISCRIMINANT ANALYSIS; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 84861323740     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12110770     Document Type: Article

References (25)

1. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist 2005;10(2):123-131. (Pubitemid 40261951)
2. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A: biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010;17(9):2427-2443.
3. Krenning EP, de Jong M, Kooij PP, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999;10(Suppl 2):S23-S29. (Pubitemid 29288527)
4. Messiou C, Orton MR, Collins DJ, et al. An exploratory open-label, non-randomised, single centre methodology study to compare dynamic contrast enhanced CT and MRI as markers of changes in vascular activity mediated by a positive control agent (Cediranib), a potent inhibitor of VEGF-driven angio [abstr]. In: Proceedings of the Nineteenth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2011; 3686.
5. Orton MR, Miyazaki K, Koh DM, et al. Optimizing functional parameter accuracy for breath-hold DCE-MRI of liver tumours. Phys Med Biol 2009;54(7):2197-2215.
6. d'Arcy JA, Collins DJ, Padhani AR, Walker-Samuel S, Suckling J, Leach MO. Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench-analysis and visualization of dynamic contrast-enhanced MR imaging data. RadioGraphics 2006;26(2):621-632. (Pubitemid 43515329)
7. Fram EK, Herfkens RJ, Johnson GA, et al. Rapid calculation of T1 using variable flip angle gradient refocused imaging. Magn Reson Imaging 1987;5(3):201-208. (Pubitemid 17133355)
8. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann H-J. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40(11):715-724. (Pubitemid 41546838)
9. Materne R, Van Beers BE, Smith AM, et al. Non-invasive quantification of liver perfusion with dynamic computed tomography and a dual-input one-compartmental model. Clin Sci (Lond) 2000;99(6):517-525. (Pubitemid 32014558)
10. Parker GJ, Roberts C, Macdonald A, et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 2006;56(5):993-1000. (Pubitemid 44691341)
11. Orton MR, Miyazaki K, Koh DM, et al. Novel method of portal delay and dispersion estimation for dual-input kinetic modelling of DCE-MRI liver data [abstr]. In: Proceedings of the Seventeenth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2009; 3615.
12. Orton MR, d'Arcy JA, Walker-Samuel S, et al. Computationally efficient vascular input function models for quantitative kinetic modelling using DCE-MRI. Phys Med Biol 2008;53(5):1225-1239. (Pubitemid 351594423)
13. Fawcett T. An introduction to ROC analysis. Pattern Recognit Lett 2006;27(8):861-874.
14. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44(3):837-845.
15. Eder JP Jr, Supko JG, Clark JW, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002;20(18):3772-3784.
16. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21(15):2831-2842. (Pubitemid 46621830)
17. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005;23(24):5464-5473.
18. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21(23):4428-4438. (Pubitemid 46621821)
19. Jarnagin WR, Schwartz LH, Gultekin DH, et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 2009;20(9):1589- 1595.
20. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21(21):3955-3964. (Pubitemid 46606209)
21. Baxter S, Wang ZJ, Joe BN, Qayyum A, Taouli B, Yeh BM. Timing bolus dynamic contrast-enhanced (DCE) MRI assessment of hepatic perfusion: Initial experience. J Magn Reson Imaging 2009;29(6):1317-1322.
22. Hagiwara M, Rusinek H, Lee VS, et al. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging - initial experience. Radiology 2008;246(3):926-934.
23. Annet L, Materne R, Danse E, Jamart J, Horsmans Y, Van Beers BE. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 2003;229(2):409-414. (Pubitemid 37310826)
24. Meijerink MR, van Cruijsen H, Hoekman K, et al. The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol 2007;17(7):1700-1713. (Pubitemid 46909659)
25. Miyazaki K, Collins DJ, Walker-Samuel S, et al. Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Eur Radiol 2008;18(7):1414-1421.